Ardeagen
- Biotech or pharma, therapeutic R&D
Ardeagen develops ADCs to treat unmet or under served markets in oncology. We have two ADCs available for licensure or some form of co-development. Both assets have completed pilot monkey tox and are ready to advance to IND enabling studies. One asset is to a novel target for which no other ADCs are in the clinic as of yet. The second target has limited competition in the ADC space but there is growing interest in this target as it is on a number of solid tumors.
Address
WoodinvilleUnited States
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}